×
About 59,736 results

ALLMedicine™ Psoriasis Center

Research & Reviews  25,607 results

Mental health outcomes in White patients versus patients with skin of color with psoria...
https://doi.org/10.5070/D327553606
Dermatology Online Journal; Kohn AH, Pourali SP et. al.

Jun 13th, 2021 - To evaluate the relationship between psoriasis and mental health in patients from different racial backgrounds. We performed a nationwide, cross-sectional study evaluating 7,519,662 (weighted) patients, comparing White patients versus patients wit...

Risk of psoriasis according to body mass index: a retrospective cohort analysis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836246
Journal of the American Academy of Dermatology; Rai P, Srivastava A et. al.

Jun 12th, 2021 - To compare bipolar vaporization of prostate (BPVP) with photoselective vaporization (PVP) of prostate in the surgical management of benign prostatic hyperplasia in terms of safety, efficacy and cost effectiveness. Data was analyzed retrospectively...

Amyloid-β: a potential link between epilepsy and cognitive decline.
https://doi.org/10.1038/s41582-021-00505-9 10.1016/S1474-4422(18)30256-4 10.1016/S1474-4422(18)30403-4 10.1016/S0140-6736(20)30750-9 10.1016/S1474-4422(16)30356-8 10.1016/S0197-4580(97)00056-0 10.1038/nrdp.2015.56 10.1093/brain/awz268 10.1038/nrneurol.2017.162 10.1016/S1474-4422(12)70291-0 10.1001/jamaneurol.2013.5847 10.1523/JNEUROSCI.5215-08.2009 10.1016/j.neurobiolaging.2016.08.025 10.1001/jamaneurol.2020.0187 10.1038/nrn.2016.141 10.3389/fneur.2020.00199 10.3233/JAD-150544 10.1016/j.neurobiolaging.2018.09.006 10.1016/S0140-6736(19)33064-8 10.3233/JAD-150096 10.1093/brain/awy022 10.1002/ca.980080612 10.1038/nature20814 10.1126/science.1566067 10.1016/j.braindev.2004.07.008 10.1016/S1474-4422(17)30044-3 10.1038/s41583-019-0240-3 10.1001/jamaneurol.2018.0629 10.1038/nn.2583 10.1016/0896-6273(95)90107-8 10.1016/S0896-6273(03)00787-6 10.1523/JNEUROSCI.0277-04.2004 10.1093/hmg/ddh019 10.1016/j.neuron.2007.07.025 10.1001/archneurol.2009.15 10.1186/s13024-017-0231-7 10.1523/JNEUROSCI.5171-13.2014 10.3389/fneur.2019.01151 10.1016/j.neurobiolaging.2018.07.009 10.1126/science.1162844 10.1016/j.brainres.2017.09.026 10.1073/pnas.1206171109 10.1038/nm1782 10.1523/JNEUROSCI.5825-09.2010 10.1101/cshperspect.a024075 10.1093/brain/awv355 10.1038/nn.2433 10.1016/j.neurobiolaging.2006.06.019 10.2174/1567205013666160129095508 10.1016/j.brainres.2010.07.061 10.1126/science.aay0198 10.1146/annurev-neuro-080317-061725 10.3233/JAD-2011-091717 10.1016/j.nbd.2015.10.019 10.1002/hipo.23129 10.1038/nn.2709 10.1038/srep20119 10.1073/pnas.0600948103 10.1101/801902 10.1016/j.neuron.2020.06.005 10.1016/S0896-6273(03)00124-7 10.3892/mmr.2014.1977 10.1126/science.1141736 10.1038/s41593-018-0289-8 10.1038/s41593-020-0687-6 10.1186/s13024-020-00393-5 10.1016/j.neuron.2012.03.023 10.1016/j.yebeh.2019.106478 10.1515/revneuro-2017-0064 10.1016/j.neuroscience.2014.11.051 10.3389/fnagi.2017.00071 10.1186/s13195-015-0110-9 10.1016/j.neurobiolaging.2014.06.009 10.1016/j.eplepsyres.2011.01.003 10.1073/pnas.1121081109 10.1016/j.cell.2012.02.046 10.1016/j.eplepsyres.2015.02.005 10.3390/ijms21239318 10.1007/s00415-019-09410-0 10.1523/JNEUROSCI.4002-14.2015 10.1074/jbc.R109.080895 10.1016/j.tins.2008.06.005 10.7554/eLife.22978 10.1111/cns.12144 10.1016/j.pharep.2014.09.013 10.1097/WNR.0000000000000601 10.1016/j.neuropharm.2017.09.031 10.3233/JAD-143162 10.2174/1567205011310040008 10.1016/0197-4580(94)00150-2 10.1177/1535759720905516 10.1016/j.neuron.2008.02.003 10.1038/nn.2801 10.1016/j.celrep.2015.04.017 10.1111/j.1528-1167.2007.01071.x 10.1093/brain/awaa441 10.2165/00002512-200320110-00001 10.1212/WNL.36.9.1226 10.1001/archneur.1990.00530080029006 10.1111/j.1528-1157.1992.tb02343.x 10.1111/j.1528-1167.2006.00554.x 10.1016/j.eplepsyres.2015.05.009 10.1007/s12017-009-8076-z 10.1111/epi.13744 10.1016/j.seizure.2018.07.015 10.1007/s00415-005-0019-5 10.1212/WNL.0000000000003048 10.1093/brain/awl237 10.1212/01.WNL.0000149761.70566.3E 10.1016/j.jns.2007.11.021 10.3233/JAD-2012-111613 10.1016/S1474-4422(16)30193-4 10.1093/brain/awq033 10.3233/JAD-181108 10.1101/cshperspect.a006338 10.1212/WNL.34.7.939 10.1159/000117218 10.1159/000093664 10.1016/j.yebeh.2008.08.012 10.1001/jamaneurol.2013.136 10.3389/fneur.2017.00360 10.3233/JAD-170392 10.1176/appi.neuropsych.15060143 10.1002/ana.24794 10.3233/JAD-160994 10.1093/brain/awy163 10.1093/ije/20.Supplement_2.S36 10.1093/oxfordjournals.aje.a117597 10.1093/oxfordjournals.aje.a114013 10.1212/WNL.40.11.1698 10.1212/WNL.37.10.1630 10.1212/WNL.39.12.1589 10.1212/WNL.41.9.1393 10.18632/aging.202299 10.1212/WNL.0000000000011080 10.1111/j.1528-1167.2006.00884.x 10.1016/j.yebeh.2005.09.004 10.1111/j.0013-9580.2005.02104.x 10.4103/0972-2327.128645 10.1001/jamaneurol.2018.1935 10.1016/j.jns.2018.09.010 10.1111/ane.12260 10.3233/JAD-121750 10.1016/j.jns.2017.08.3742 10.1001/jamaneurol.2016.6091 10.1016/j.eplepsyres.2017.09.006 10.1016/j.jns.2006.11.004 10.1001/archgenpsychiatry.2011.72 10.1212/WNL.0b013e318230a16c 10.1016/j.yebeh.2019.106592 10.1093/neuonc/nos288 10.1016/j.trci.2019.07.012 10.1016/j.yebeh.2010.01.015 10.1016/j.nicl.2015.02.009 10.1016/j.pneurobio.2018.07.003 10.1111/j.1460-9568.2010.07379.x 10.1016/j.eplepsyres.2007.01.002 10.1016/j.yebeh.2016.01.011 10.1371/journal.pone.0174630 10.3233/JAD-150342 10.1038/s41582-019-0205-1 10.1212/WNL.0000000000002683 10.1001/jamaneurol.2019.1424 10.1016/j.neurobiolaging.2017.12.018 10.1007/s00415-018-9100-8 10.1212/WNL.0b013e3181f39a78 10.1016/j.biopsych.2008.02.016 10.1002/mds.26656 10.1136/jnnp.2007.127878 10.1016/S1474-4422(06)70600-7 10.1001/jamanetworkopen.2019.16439 10.3233/JAD-150446 10.1001/archneurol.2011.666 10.1212/WNL.0b013e318245d295 10.1038/s41598-019-47638-y 10.1016/S1474-4422(06)70501-4 10.1073/pnas.1708106114 10.1016/j.nbd.2018.05.020 10.1093/brain/awz381 10.1093/brain/aww187 10.1093/brain/awaa397 10.1523/JNEUROSCI.4152-10.2011 10.1016/j.nbd.2017.08.015 10.1083/jcb.201407065 10.1016/j.nbd.2014.01.007 10.1038/nature07761 10.1016/j.neuron.2013.06.036 10.1038/nn.3178 10.1016/j.yebeh.2019.106861 10.1212/WNL.0000000000009061 10.1177/0333102416683925 10.1111/j.1468-1331.2007.01907.x 10.1111/epi.16068 10.2174/1570159X17666181227165722 10.2165/00023210-200216100-00004 10.1016/S1059-1311(98)80073-3 10.1016/j.yebeh.2018.01.028 10.1111/j.1528-1167.2006.00956.x
Nature Reviews. Neurology; Romoli M, Sen A et. al.

Jun 12th, 2021 - Since the beginning of the Coronavirus Disease-19 (COVID-19) pandemic, Severe Acute Respiratory Syndrome-CoV-2 (SARS-CoV-2) infection has been a serious challenge for immune-compromised patients with immune-mediated inflammatory diseases (IMIDs). ...

Sweet or Bland Dreams? Taste Loss in Isolated REM-Sleep Behavior Disorder and Parkinson...
https://doi.org/10.1002/mds.28692
Movement Disorders : Official Journal of the Movement Dis... Nigam M, Ayadi I et. al.

Jun 12th, 2021 - Psoriasis, a chronic inflammatory dermatosis, has been associated with chronic kidney disease or end-stage renal disease. However, the association of the changes or amount of proteinuria with psoriasis development has not been evaluated. Using the...

see more →

Guidelines  207 results

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specifi...
https://doi.org/10.1111/jdv.16926
Journal of the European Academy of Dermatology and Venere... Nast A, Smith C et. al.

Feb 6th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 6th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

Portuguese recommendations for the treatment of psoriasis with biologic therapy.
https://doi.org/10.1684/ejd.2020.3945
European Journal of Dermatology : EJD; Torres T, Tavares Bello R et. al.

Dec 10th, 2020 - Psoriasis is a highly prevalent chronic, inflammatory multisystem disease with a considerable impact on patients' quality of life and the healthcare system. This report presents the recommendations developed by the Portuguese Psoriasis Group of th...

Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
https://onlinelibrary.wiley.com/doi/10.1002/acr2.11196
ACR Open Rheumatology; Liphardt AM

Nov 24th, 2020 - The objective of this study was to compare the impact of psoriatic disease (psoriatic arthritis [PsA] and psoriasis) and rheumatoid arthritis (RA) on objective and subjective parameters of hand function.

Bone Mineral Density, Osteoporosis, and Fracture Risk in Adult Patients with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Observational Studies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699147/
Journal of Clinical Medicine; Chen TL

Nov 18th, 2020 - Awareness of psoriasis-related comorbidities has been established in the current guidelines; however, evidence regarding the association of bone density or bone fragility with psoriatic disease remains inconclusive.

see more →

Drugs  1,369 results see all →

Clinicaltrials.gov  28,561 results

Cross-Sectional Study Finds Chronic Skin Conditions Have Highest Opioid Prescribing Rates
https://www.medscape.com/viewarticle/953102

Jun 14th, 2021 - Opioids were prescribed most often for vitiligo, hemangioma, pemphigus, atopic dermatitis, and psoriasis, according to a study that used national ambulatory care data to evaluate pain medication use at dermatology visits. "Overall, opioid prescrib...

Fast Five Quiz: Systemic Treatments for Plaque Psoriasis
https://reference.medscape.com/viewarticle/929577

Jun 13th, 2021 - Approximately 125 million people around the world have psoriasis, a chronic, relapsing inflammatory skin disorder. Several clinical variants of psoriasis are recognized, but plaque psoriasis is the most common. Psoriasis is associated with a signi...

Psoriasis Treatment With Biologics: 5 Things to Know
https://www.medscape.com/viewarticle/951993

Jun 13th, 2021 - Psoriasis affects at least 100 million people worldwide, with plaque psoriasis (also referred to as psoriasis vulgaris) being the most common form. Although many different medication options are available for psoriasis, the type of treatment presc...

Mental health outcomes in White patients versus patients with skin of color with psoria...
https://doi.org/10.5070/D327553606
Dermatology Online Journal; Kohn AH, Pourali SP et. al.

Jun 13th, 2021 - To evaluate the relationship between psoriasis and mental health in patients from different racial backgrounds. We performed a nationwide, cross-sectional study evaluating 7,519,662 (weighted) patients, comparing White patients versus patients wit...

Risk of psoriasis according to body mass index: a retrospective cohort analysis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836246
Journal of the American Academy of Dermatology; Rai P, Srivastava A et. al.

Jun 12th, 2021 - To compare bipolar vaporization of prostate (BPVP) with photoselective vaporization (PVP) of prostate in the surgical management of benign prostatic hyperplasia in terms of safety, efficacy and cost effectiveness. Data was analyzed retrospectively...

see more →

News  3,773 results

Cross-Sectional Study Finds Chronic Skin Conditions Have Highest Opioid Prescribing Rates
https://www.medscape.com/viewarticle/953102

Jun 14th, 2021 - Opioids were prescribed most often for vitiligo, hemangioma, pemphigus, atopic dermatitis, and psoriasis, according to a study that used national ambulatory care data to evaluate pain medication use at dermatology visits. "Overall, opioid prescrib...

Fast Five Quiz: Systemic Treatments for Plaque Psoriasis
https://reference.medscape.com/viewarticle/929577

Jun 13th, 2021 - Approximately 125 million people around the world have psoriasis, a chronic, relapsing inflammatory skin disorder. Several clinical variants of psoriasis are recognized, but plaque psoriasis is the most common. Psoriasis is associated with a signi...

Psoriasis Treatment With Biologics: 5 Things to Know
https://www.medscape.com/viewarticle/951993

Jun 13th, 2021 - Psoriasis affects at least 100 million people worldwide, with plaque psoriasis (also referred to as psoriasis vulgaris) being the most common form. Although many different medication options are available for psoriasis, the type of treatment presc...

GRAPPA Refines Recommendations on Psoriatic Disease Treatment
https://www.medscape.com/viewarticle/952582

Jun 7th, 2021 - The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has included more drugs and data and is moving toward a slightly more stepped approach to treating some forms of psoriatic disease in the latest iteration of their...

Secukinumab, IL-17 Inhibitor, Approved for Pediatric Psoriasis
https://www.medscape.com/viewarticle/952321

Jun 1st, 2021 - The Food and Drug Administration has approved the interleukin-17 inhibitor secukinumab (Cosentyx) for the treatment of moderate to severe plaque psoriasis in pediatric patients aged 6 years and older who are candidates for systemic therapy or phot...

see more →

Patient Education  219 results see all →